GlassScriptPhysician profile
Scott R Strauss
NPI 1811986391
$6,642.06
in general payments reported to CMS, 2019-2025
31 companies · $1,098 in 2025
The $1,098 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $622 · 2020: $1,295 · 2021: $978 · 2022: $809 · 2023: $703 · 2024: $1,137 · 2025: $1,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,937.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,552.88 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,211.72 | 2019-2025 | Farxiga, Breztri |
| Lilly USA, LLC | $676.17 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $618.19 | 2019-2025 | |
| Amarin Pharma, INC. | $527.33 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $373.46 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $269.11 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $201.17 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $154.70 | 2019-2025 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $144.24 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $138.48 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $110.67 | 2024 | |
| Daiichi Sankyo INC. | $83.97 | 2021-2025 | Injectafer |
| Biohaven Pharmaceutical Holding Company LTD. | $80.73 | 2022 | |
| Abbott Laboratories | $71.79 | 2021-2024 | Freestyle Libre 3 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $55.67 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $42.66 | 2022-2024 | |
| Medtronic, INC. | $41.35 | 2024-2025 | Vanta Adaptivestim, Intellis Adaptivestim |
| Boston Scientific Corporation | $41.01 | 2025 | General - Dbs |
| Axsome Therapeutics, INC. | $39.30 | 2023-2025 | Sunosi, Symbravo |
| Dynavax Technologies Corporation | $35.54 | 2024 | Heplisav-B |
| Arbor Pharmaceuticals, INC. | $28.14 | 2020 | |
| Dexcom, INC. | $21.79 | 2024 | Dexcom G6 Transmitter |
| Bavarian Nordic A/S | $17.65 | 2025 | Vivotif |
| E.R. Squibb & Sons, L.L.C. | $16.83 | 2024 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.01 | 2019 | |
| Mylan Specialty L.P. | $15.00 | 2019 | |
| Vbi Vaccine (Delaware) INC. | $14.47 | 2022 | |
| Alkermes, INC. | $14.23 | 2025 | Vivitrol |
| Takeda Pharmaceuticals U.S.A., INC. | $14.20 | 2019 | |
| Intuity Medical INC | $13.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Strauss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.